NCT07475533Not yet recruiting
Low-flow Versus Minimal-flow Sevoflurane Anesthesia During Robot-assisted Laparoscopic Radical Prostatectomy
A Prospective Randomized Study Comparing Low-Flow (1 L/Min) and Minimal-Flow (0.5 L/Min) Sevoflurane Anesthesia in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy
Source: ClinicalTrials.gov · Last updated 15 Apr 2026
Brief summary (registry, in English)
Study Synopsis This protocol is formatted for ClinicalTrials.gov-style registration and manuscript-facing documentation. It is based on the uploaded Turkish ethics protocol and keeps the original core design: comparison of low-flow and minimal-flow sevoflurane anesthesia in robot-assisted laparoscopic radical prostatectomy. Background and Rationale Robot-assisted laparoscopic radical prostatectomy (RALRP) is increasingly preferred for localized prostate cancer because of lower blood loss, reduced transfusion requirements, shorter hospitalization, and lower complication rates compared with open surgery. However, RALRP requires carbon dioxide pneumoperitoneum and steep Trendelenburg positioning, both of which may adversely affect respiratory mechanics, gas exchange, and hemodynamic stability. Low-flow and minimal-flow anesthesia may improve humidification and warming of inspired gases, reduce inhalational agent consumption, decrease environmental waste, and potentially lower overall cost. Despite these theoretical and practical advantages, evidence remains limited regarding the physiologic safety and performance of minimal-flow sevoflurane anesthesia during long robotic pelvic surgery performed under pneumoperitoneum and steep Trendelenburg positioning. Accordingly, this randomized prospective trial will compare low-flow (1 L/min) and minimal-flow (0.5 L/min) sevoflurane anesthesia during RALRP with respect to respiratory parameters, arterial blood gas values, intraoperative oxygenation variables, anesthetic consumption, and selected postoperative biochemical markers.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 8 Mar 2026
- Start date
- 20 Mar 2026
- Primary completion date
- 20 Apr 2026
- Lead sponsor
- Ankara City Hospital Bilkent
- Diseases
- Prostate cancer
- NCT number
- NCT07475533
What you commit to
- Study type: Interventional
- Planned participants: 70
- From 20 Mar 2026 to the primary completion date, 20 Apr 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Male patients aged 18 years or older.
- ASA physical status I-II.
- Scheduled for elective robot-assisted laparoscopic radical prostatectomy.
- Provision of written informed consent. Exclusion Criteria
- ASA physical status III-V.
- Severe cardiac, respiratory, hepatic, or renal disease.
- Mental status disorder or significant hearing impairment that prevents consent or communication.
- Known anxiety, depression, or other psychiatric disorder judged to interfere with study participation.
- Withdrawal of consent or investigator decision for safety reasons.
Age in the registry: 18 years to - · Sex: Male · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.